INCA033989
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for INCA033989, covering 2026-03-24 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms [Phase 1]